Avalo Therapeutics, Inc.
AVTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.10 | -0.01 | 0.01 | -0.00 |
| FCF Yield | -9.20% | -21.08% | -11.23% | -19.34% |
| EV / EBITDA | -4.94 | -0.65 | 2.75 | 4.24 |
| Quality | ||||
| ROIC | -16.39% | -16.40% | -10.99% | -9.22% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 54.69% |
| Cash Conversion Ratio | 0.53 | 0.55 | 0.72 | 0.43 |
| Growth | ||||
| Revenue 3-Year CAGR | -55.97% | -70.38% | -70.60% | -70.98% |
| Free Cash Flow Growth | -43.68% | -20.44% | 37.14% | -30.51% |
| Safety | ||||
| Net Debt / EBITDA | 0.88 | 2.17 | 8.55 | 10.12 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -6.35 |